SCHEDULE 13G/A: Goldman Sachs Discloses 2.8% Passive Stake in Elevation Oncology

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.8% in Elevation Oncology, Inc. as of December 31, 2024.

Summary

• The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, have jointly filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of Common Stock, par value $0.0001 per share, in ELEVATION ONCOLOGY, INC.
• As of December 31, 2024, the reporting persons collectively beneficially own 1,683,356 shares.
• This aggregate amount represents 2.8% of Elevation Oncology, Inc.'s class of securities.
• Both Goldman Sachs entities report shared voting power and shared dispositive power over all 1,683,356 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not convey a strong positive or negative sentiment. It is neutral in tone, as expected for a regulatory filing of this type.

Positives

• The disclosure of a 2.8% stake by a major financial institution like Goldman Sachs could be viewed positively by the market, indicating institutional interest in Elevation Oncology, Inc.

Negatives

• The document does not contain any negative information regarding Elevation Oncology, Inc. or the reporting entities' investment.

Risks

• The document itself is a disclosure of beneficial ownership and does not detail specific risks related to Elevation Oncology, Inc.'s operations or financial health. The primary risk implied is the general market risk associated with holding equity in a publicly traded company.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Elevation Oncology, Inc.'s future performance or strategic outlook.

Management Comments

• The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a routine disclosure by a major institutional investor, Goldman Sachs, indicating a passive stake in a biotechnology company, Elevation Oncology. Such filings provide transparency into significant ownership positions and can signal institutional confidence or interest in a particular sector or company, though a 2.8% stake is not a controlling interest.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of Goldman Sachs' stake may provide a degree of confidence or validation for existing shareholders, indicating institutional interest in the company.
• Investment Professionals: Provides transparency into institutional holdings, which can be used for market analysis and tracking significant investor positions.

Key Dates

Keywords

Elevation Oncology, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Oncology, Biotechnology